NDAINJECTIONINJECTABLE
Approved
Jun 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ULTRATAG (kit for the preparation of technetium tc 99m red blood cells) by Curium Pharma is clinical pharmacology in vitro tc 99m red blood cell labeling is accomplished by adding 1. First approved in 1991.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRATAG is an in vitro kit for preparing technetium Tc 99m-labeled autologous red blood cells used for gamma scintigraphic imaging of the blood pool. The kit uses a multi-step chemical process to efficiently label patient red blood cells with radioactive pertechnetate, achieving ≥95% labeling efficiency. Following intravenous reinjection, the labeled cells distribute throughout the blood pool and enable visualization of cardiac function and blood flow abnormalities.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential headcount constraints and shift toward defensive positioning or transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY In vitro Tc 99m red blood cell labeling is accomplished by adding 1.0 to 3.0 milliliters of autologous whole blood, anticoagulated with heparin or Anticoagulant Citrate Dextrose Solution (ACD), to the reaction vial. A portion of the stannous ion in the reaction vial diffuses…
Worked on ULTRATAG at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.